Oak Ridge Investments LLC Sells 779 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Oak Ridge Investments LLC lessened its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 1.9% in the first quarter, HoldingsChannel.com reports. The fund owned 40,093 shares of the company’s stock after selling 779 shares during the period. Oak Ridge Investments LLC’s holdings in Axsome Therapeutics were worth $2,270,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. State of New Jersey Common Pension Fund D lifted its holdings in shares of Axsome Therapeutics by 0.6% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 29,684 shares of the company’s stock worth $2,418,000 after acquiring an additional 169 shares during the period. Exane Derivatives lifted its holdings in shares of Axsome Therapeutics by 4.4% during the 1st quarter. Exane Derivatives now owns 4,447 shares of the company’s stock worth $252,000 after acquiring an additional 189 shares during the period. WCM Investment Management LLC lifted its holdings in shares of Axsome Therapeutics by 0.3% during the 4th quarter. WCM Investment Management LLC now owns 72,107 shares of the company’s stock worth $5,875,000 after acquiring an additional 197 shares during the period. Swiss National Bank lifted its holdings in shares of Axsome Therapeutics by 0.3% during the 4th quarter. Swiss National Bank now owns 63,200 shares of the company’s stock worth $5,149,000 after acquiring an additional 200 shares during the period. Finally, D.A. Davidson & CO. lifted its holdings in shares of Axsome Therapeutics by 2.9% during the 4th quarter. D.A. Davidson & CO. now owns 7,205 shares of the company’s stock worth $587,000 after acquiring an additional 205 shares during the period. 60.61% of the stock is owned by institutional investors.

Shares of NASDAQ AXSM opened at $67.57 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 7.61 and a current ratio of 7.61. Axsome Therapeutics, Inc. has a 52-week low of $50.05 and a 52-week high of $90.00. The company has a 50 day simple moving average of $57.49. The firm has a market cap of $2.54 billion, a PE ratio of -25.40 and a beta of 2.53.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Sunday, May 9th. The company reported ($0.78) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.83) by $0.05. On average, analysts expect that Axsome Therapeutics, Inc. will post -3.74 EPS for the current year.

In other news, Director Mark Coleman acquired 500 shares of Axsome Therapeutics stock in a transaction dated Wednesday, May 12th. The shares were bought at an average cost of $58.15 per share, with a total value of $29,075.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 26.10% of the company’s stock.

AXSM has been the subject of a number of recent analyst reports. BTIG Research reaffirmed a “buy” rating on shares of Axsome Therapeutics in a report on Wednesday, May 12th. HC Wainwright upped their price objective on shares of Axsome Therapeutics from $210.00 to $225.00 and gave the stock a “buy” rating in a research report on Tuesday, April 27th. Mizuho lowered their price objective on shares of Axsome Therapeutics from $120.00 to $118.00 and set a “buy” rating for the company in a research report on Tuesday, March 2nd. Morgan Stanley upped their price objective on shares of Axsome Therapeutics from $104.00 to $105.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 26th. Finally, Berenberg Bank initiated coverage on shares of Axsome Therapeutics in a research report on Thursday. They set a “buy” rating and a $112.00 price objective for the company.
One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. Axsome Therapeutics has an average rating of “Buy” and a consensus target price of $130.86.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation.

Featured Article: Trading Options- What is a Strangle?

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM).

Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.